Comparison · NCT02939014-sae
Brentuximab Vedotin 1.8 mg/kg (HL) vs Brentuximab Vedotin 1.8 mg/kg (sALCL): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Brentuximab Vedotin 1.8 mg/kg (HL) vs Brentuximab Vedotin 1.8 mg/kg (sALCL): serious adverse events. Trial comparisons, record NCT02939014-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02939014-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0333 | 0.00591 | 0.167 | wilson | |
| Risk in group 2 | 0.111 | 0.0199 | 0.435 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0778 | -0.403 | 0.0838 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.3 | 0.0208 | 4.33 | log | |
| Odds ratio, group 1 over group 2 | 0.276 | 0.0155 | 4.92 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Brentuximab Vedotin 1.8 mg/kg (HL) than on Brentuximab Vedotin 1.8 mg/kg (sALCL) | 12.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab vedotin 1.8 mg/kg, IV, infusion on Day 1 of each 3-week cycle until the sooner of disease progression, unacceptable toxicity, or completion of 16 cycles in participants with Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL). | 1 | 30 | EG000 |
| Group 2 | Brentuximab Vedotin 1.8 mg/kg (sALCL) | Brentuximab vedotin 1.8 mg/kg, IV, infusion on Day 1 of each 3-week cycle until the sooner of disease progression, unacceptable toxicity, or completion of 16 cycles in participants with Relapsed/Refractory Systemic Anaplastic Large Cell Lymphoma (sALCL). | 1 | 9 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- All-Cause Mortality: up to 3.2 years; Serious and Other Adverse Events: First dose of study drug up to 30 days post last dose of study drug (up to 12 months)
Source ClinicalTrials.gov
Trial
- Title
- Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
- NCT number
- NCT02939014
- Phases
- PHASE2
- Conditions
- Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic
- Interventions
- Brentuximab Vedotin
- Lead sponsor
- Takeda
- Results first posted
- 2019-09-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02939014?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02939014-sae